LifeVantage Corp (LFVN)
NASDAQ:LFVN
Top Page
LifeVantage
(NASDAQ:LFVN)
Select Model
Select Model
Rating:56Neutral
Price Target:
$4.50
▼(-33.43% Downside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by mixed fundamentals: strong margins and a solid balance sheet are offset by deteriorating cash flow and recent revenue contraction. Technicals add pressure due to a clear downtrend, while valuation (low P/E and dividend yield) provides meaningful support. Earnings call takeaways are mixed—supportive guidance and capital returns are outweighed by steep YoY revenue decline, margin pressure, weak cash generation, and leadership transition risk.
Positive Factors
High Gross Margins & Improving Profitability
Sustained ~80% gross margins and a materially improved TTM net margin provide durable operating leverage: high product gross margins buffer the business against volume swings, support reinvestment in R&D and marketing, and underpin long-term earnings resilience even amid top-line variability.
Negative Factors
Material Revenue Decline & Distributor Attrition
A large YoY revenue drop and steep declines in active accounts indicate weakening distributor engagement and recurring demand. In a direct-selling model, sustained account attrition undermines long-term revenue visibility and makes recovery dependent on costly reactivation or recruiting efforts, pressuring unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins & Improving Profitability
Sustained ~80% gross margins and a materially improved TTM net margin provide durable operating leverage: high product gross margins buffer the business against volume swings, support reinvestment in R&D and marketing, and underpin long-term earnings resilience even amid top-line variability.
Read all positive factors
LifeVantage (LFVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$53.09M
Dividend Yield2.81%
Average Volume (3M)110.67K
Price to Earnings (P/E)70.5
Beta (1Y)0.01
Revenue Growth16.77%
EPS Growth143.30%
CountryUS
Employees222
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.02
Shares Outstanding12,793,359
10 Day Avg. Volume78,718
30 Day Avg. Volume110,671
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.63
Price to Sales (P/S)0.70
P/FCF Ratio15.25
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.32
Enterprise Value/Ebitda4.52
Forecast
1Y Price Target
$5.00Price Target Upside-26.04% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.78
Revenue Forecast (FY)$204.89M
LifeVantage Business Overview & Revenue Model
Company Description
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, ba...
How the Company Makes Money
LifeVantage primarily makes money by selling its health and wellness products through a direct selling (multi-level/affiliate-style) distribution network. Revenue is generated mainly from product sales to and through independent distributors (who ...
LifeVantage Key Performance Indicators (KPIs)
LifeVantage Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Negative
The quarter showed clear operational progress on strategic initiatives (LoveBiome integration, new product launches, Shopify partnership, continued R&D validation) and the company maintained a clean balance sheet and shareholder-friendly capital actions. However, material near-term financial headwinds dominated the call: a 27.8% YoY revenue decline driven by steep MINDBODY GLP-1 weakness, an inventory reserve, declines in active accounts, margin compression, and weaker cash generation. While management outlined credible mitigation steps and growth levers, the immediate financial deterioration and market-driven challenges to the GLP-1 offering outweigh the positive strategic developments.Positive Updates
LoveBiome Acquisition Driving Early Momentum
LoveBiome contributed $4.1M of product revenue in Q2 following the October acquisition; successful operational integration, realization of synergies, and multiple product launches (Axila X, Phytopower B) with additional LoveBiome products to launch in coming months. $3.7M cash paid at close plus potential future earn-out.
Negative Updates
Significant Year-Over-Year Revenue Decline
Net revenue was $48.9M in Q2, down 27.8% YoY from $67.8M; the decline was driven primarily by MINDBODY GLP-1 sales falling $16.2M versus prior year.
Read all updates
Q2-2026 Updates
Positive
Negative
LoveBiome Acquisition Driving Early Momentum
LoveBiome contributed $4.1M of product revenue in Q2 following the October acquisition; successful operational integration, realization of synergies, and multiple product launches (Axila X, Phytopower B) with additional LoveBiome products to launch in coming months. $3.7M cash paid at close plus potential future earn-out.
Read all positive updates
Company Guidance
LifeVantage gave fiscal 2026 guidance of revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million (implying an adjusted EBITDA margin of roughly 7.5%–10.3% depending on the revenue/EBITDA mix), and adjusted earnings per share of $0.60 to $0.80 on a fully diluted basis; management also announced a new $60 million share repurchase authorization (replacing the prior program) through 12/31/2027 and declared a quarterly cash dividend of $0.45 per share payable 03/16/2026 to shareholders of record on 03/02/2026.LifeVantage Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 210.05M | 228.53M | 200.16M | 213.40M | 206.36M | 220.18M |
| Gross Profit | 165.40M | 183.67M | 158.72M | 170.01M | 168.26M | 181.99M |
| EBITDA | 11.87M | 15.36M | 7.91M | 7.84M | 7.96M | 21.07M |
| Net Income | 7.86M | 9.80M | 2.94M | 2.54M | 3.12M | 12.89M |
Balance Sheet | ||||||
| Total Assets | 61.17M | 71.96M | 60.30M | 66.12M | 70.71M | 78.73M |
| Cash, Cash Equivalents and Short-Term Investments | 10.18M | 20.20M | 16.89M | 21.61M | 20.19M | 23.17M |
| Total Debt | 10.69M | 11.68M | 13.61M | 13.09M | 15.76M | 18.18M |
| Total Liabilities | 28.18M | 37.32M | 34.31M | 31.47M | 39.19M | 41.92M |
| Stockholders Equity | 32.99M | 34.64M | 25.99M | 34.65M | 31.52M | 36.81M |
Cash Flow | ||||||
| Free Cash Flow | 1.70M | 10.51M | 9.95M | 3.76M | 6.43M | 6.43M |
| Operating Cash Flow | 3.75M | 11.88M | 12.20M | 6.83M | 7.96M | 7.96M |
| Investing Cash Flow | -5.80M | -1.37M | -2.25M | -3.06M | -1.53M | -1.53M |
| Financing Cash Flow | -9.40M | -7.60M | -14.42M | -2.36M | -8.95M | -8.95M |
LifeVantage Technical Analysis
Negative
6.76
Price Trends
4.74
Negative
5.50
Negative
8.25
Negative
Market Momentum
-0.23
Positive
37.74
Neutral
32.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 6.76 is above the 20-day moving average (MA) of 4.43, above the 50-day MA of 4.74, and below the 200-day MA of 8.25, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 32.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.
LifeVantage Risk Analysis
LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeVantage Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.57B | 5.80 | -36.19% | ― | -0.78% | 265.56% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $471.48M | 19.90 | 12.18% | ― | 6.62% | -7.85% | |
56 Neutral | $53.09M | 70.54 | 24.97% | 2.81% | 16.77% | 143.30% | |
53 Neutral | $334.26M | -50.11 | 2.03% | ― | 5.88% | -68.62% | |
45 Neutral | $79.16M | -0.21 | -111.73% | ― | -10.13% | -532.32% |
* Consumer Defensive Sector Average
LFVN
LifeVantage
4.15
-9.77
-70.18%
HLF
Herbalife
15.23
8.62
130.41%
NATR
Nature's Sunshine Products
26.93
14.82
122.38%
HAIN
Hain Celestial
0.87
-2.18
-71.48%
USNA
USANA Health
18.11
-6.38
-26.05%
ABVE
Above Food Ingredients
0.73
0.18
33.45%
LifeVantage Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackDividendsFinancial Disclosures
LifeVantage Reports Weaker Q2 Results, Launches Buyback Program
Negative
Feb 4, 2026
On January 30, 2026, LifeVantage announced that President and CEO Steven R. Fife plans to retire from his roles, including his board seat, with his resignation expected to take effect in April 2026, and the company emphasized that his decision was...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.